Vaccine therapies in malignant glioma
Document Type
Article
Abstract
Glioblastoma is a grade IV astrocytoma that is widely accepted in clinical neurosurgery as being an extremely lethal diagnosis. Long-term survival rates remain dismal, and even when tumors undergo gross resection with confirmation of total removal on neuroimaging, they invariably recur with even greater virulence. Standard therapeutic modalities as well as more contemporary treatments have largely resulted in disappointing improvements. However, the therapeutic potential of vaccine immunotherapy for malignant glioma should not be underestimated. In contrast to many of the available treatments, vaccine immunotherapy is unique because it offers the means of delivering treatment that is highly specific to both the patient and the tumor. Peptide, heat-shock proteins, and dendritic cell vaccines collectively encapsulate the majority of research efforts involving vaccine-based treatment modalities. In this review, important recent findings for these vaccine types are discussed in the context of ongoing clinical trials. Broad challenges to immunotherapy are also considered.
Medical Subject Headings
Animals; Brain Neoplasms (immunology, therapy); Cancer Vaccines (therapeutic use); Dendritic Cells (immunology); Glioma (immunology, therapy); Heat-Shock Proteins (immunology); Humans; Peptides (immunology)
Publication Date
1-1-2015
Publication Title
Current neurology and neuroscience reports
E-ISSN
1534-6293
Volume
15
Issue
1
First Page
508
PubMed ID
25431096
Digital Object Identifier (DOI)
10.1007/s11910-014-0508-y
Recommended Citation
Oh, Taemin; Sayegh, Eli T.; Fakurnejad, Shayan; Oyon, Daniel; Lamano, Jonathan Balquiedra; DiDomenico, Joseph David; Bloch, Orin; and Parsa, Andrew T., "Vaccine therapies in malignant glioma" (2015). Neurosurgery. 2184.
https://scholar.barrowneuro.org/neurosurgery/2184